Vaccine Economic Impact

Billions of dollars saved

If used in all countries eligible for support from Gavi, the Vaccine Alliance, rotavirus vaccines could prevent an estimated 180,000 deaths and avert 6 million clinic and hospital visits each year, thereby saving US$68 million annually in treatment costs1.

Recent studies show that national rotavirus vaccination programs will be highly cost-effective and also reduce healthcare costs due to rotavirus-related illness2-6.

  • In the US, in just four years, rotavirus vaccination saved nearly US$1 billion by preventing hospitalizations, emergency visits and doctors’ visits among children under age 56.
COUNTRYCASES AVERTEDDEATHS AVERTEDHEALTHCARE COSTS AVERTEDDATE RANGE
Iran [3]35.1 million266US$280 million2014-2023
Kenya [2]1.2 million 61,000US$30 million2014-2033
Senegal [7]2 million8,500US$8 million2014-2033
Uganda [2]4 million70,000US$10 million2016-2035
Malawi [5]1 million4,313US$8 million2014-2033

Rotavirus Vaccines are Cost-Effective

Cost effectiveness is dependent on a number of variables, including vaccine price, relative coverage, herd protection, vaccine effectiveness, the number of deaths and hospitalizations, and rate of waning protection8. These all contribute to the overall healthcare costs averted through rotavirus vaccination.

A cost-effectiveness analysis focusing on countries supported by Gavi co-financing found rotavirus vaccines to be cost-effective in the entire cohort of eligible countries, even when herd protection is not taken into account. Rotavirus vaccines were also found to be cost-effective in each Gavi country individually1.

Using WHO-CHOICE guidelines, rotavirus vaccines are projected to be highlight cost-effective8:

  • At US$5 per each dose of rotavirus vaccine, the cost-effectiveness in the low-, lower-middle- and upper-middle-income groups was US$88, US$291, and US$329, respectively, for each DALY averted9.

1. Atherly, D.E., et al., Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine, 2012. 30 Suppl 1: p. A7-14.

2. Sigei, C.O., J.; Mvundura, M.; Madrid, Y.; Clark, AD., Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. Vaccine, 2015. 33(Supplement 1): p. A109-A118.

3. Javanbakht, M., et al., Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran. Vaccine, 2015. 33 Suppl 1: p. A192-200.

4. Diop, A., et al., Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis. Vaccine, 2015. 33, Supplement 1: p. A119-A125.

5. Bar-Zeev, N., et al., Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data. Clin Infect Dis, 2016. 62 Suppl 2: p. S220-8.

6. Leshem, E., et al., Rotavirus vaccines and health care utilization for diarrhea in the United States (2007-2011). Pediatrics, 2014. 134(1): p. 15-23.

7. Diop, A., et al., Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis. Vaccine, 2015. 33 Suppl 1: p. A119-25.

8. Clark, A., et al., TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. Vaccine, 2013. 31 Suppl 3: p. C19-29.

9. Rheingans, R.D., et al., Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis, 2009. 200 Suppl 1: p. S16-27.